Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049857 | 0.83 | NPC1 (0.53) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6454205 | 0.83 | NR1H2 (0.56) | HPGDNPC1RAB9ASMN1; SMN2DCUN1D1 | |
| SCHEMBL6450010 | 0.81 | MAPT (0.53) | NPC1RAB9ASMN1; SMN2MEN1MAPT | |
| SCHEMBL6453051 | 0.80 | THRB (0.39) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6450407 | 0.80 | FEN1 (0.43) | NPC1RAB9ASMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL6453795 | 0.79 | GRK6 (0.42) | ALDH1A1HPGDSMN1; SMN2MEN1MAPT | |
| SCHEMBL6449767 | 0.77 | SMN1; SMN2 (0.65) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6449955 | 0.77 | JAK2 (0.49) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6448859 | 0.77 | GRK6 (0.44) | NPC1RAB9ASMN1; SMN2MEN1TSHR | |
| SCHEMBL5314102 | 0.76 | IDO1 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | ALDH1A1 287/4885HPGD 258/4885NPC1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.